Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
@Cautious
DV said "wait for Rns’s to come out."
this sounds a bit ominous - what was the tone of voice he said this in? Did he seem to mean RNSs indicating passing of mandatory notification thresholds for significant shareholders, or good news, or bad news?
Thought it worth recapping on the advantages of having Orphan Drug Designation (ODD)
Securing orphan drug designation from regulatory agencies such as the FDA offers a number of advantages to treatment developers and, ultimately, to patients:
* Financial Incentives: Companies receive various financial benefits, including tax credits for clinical research costs, grants for drug development, and potential fee waivers, making the development process more economically viable.
*Market Exclusivity: Upon approval, the drug enjoys a period of market exclusivity, typically seven years in the United States, during which competitors cannot market a generic version. This exclusivity can be a significant financial advantage.
* Regulatory Support: Companies often receive more extensive guidance and support from regulatory agencies during the drug development process, which can expedite the time to market.
* Lower Regulatory Hurdles: The criteria for clinical trial success may be more flexible for orphan drugs, given the rarity and severity of the conditions they treat. This can make it easier to demonstrate efficacy and safety.
* Access to Funding: ODD can make a drug candidate more attractive to investors, as the designation often implies a faster, less expensive, and less risky development pathway.
I'm not making up the rules.
Look at the teal coloured part of the graphic in the explainer here
https://www.raps.org/news-and-articles/news-articles/2017/12/regulatory-explainer-everything-you-need-to-know
@Nolupus The priority review voucher gives priority (4 months faster turnaround) in the FDA review. It would make absolutely NO SENSE for these vouchers to be granted after the FDA review is concluded with approval.
Wasn't the plan always that the Mayo Clinic would not keep the shares, they were just part of the terms of the initial collaboration? I don't think the Mayo Clinic board would want to be managing an investment portfolio.
The mention of IB Neuro is in the "Methods" section, which is where it should be. Nature papers have a very rigidly enforced structuring, and they are not all that often read from start to finish. People who are interested in how the results were obtained will look in the "Methods" section.
It would count but diluted, right?
Imagine 100 shares for simplicity. TB starts with 30 shares. TB sells 2, and IQAI buys them and takes them into registry and cancels them. TB then owns 28/98 shares = 28.57% of the company, rather than 30%. Thus freeing up 0.43% of the market cap available to be used in converting CLNs.
Great article! I confess I hadn't completely grasped all the advantages of having Orphan Drug Designation (ODD)
Securing orphan drug designation from regulatory agencies such as the FDA offers a number of advantages to treatment developers and, ultimately, to patients:
* Financial Incentives: Companies receive various financial benefits, including tax credits for clinical research costs, grants for drug development, and potential fee waivers, making the development process more economically viable.
*Market Exclusivity: Upon approval, the drug enjoys a period of market exclusivity, typically seven years in the United States, during which competitors cannot market a generic version. This exclusivity can be a significant financial advantage.
* Regulatory Support: Companies often receive more extensive guidance and support from regulatory agencies during the drug development process, which can expedite the time to market.
* Lower Regulatory Hurdles: The criteria for clinical trial success may be more flexible for orphan drugs, given the rarity and severity of the conditions they treat. This can make it easier to demonstrate efficacy and safety.
* Access to Funding: ODD can make a drug candidate more attractive to investors, as the designation often implies a faster, less expensive, and less risky development pathway.
I think someone explained it a week or two ago - MMs drop the bid to encourage people to sell for fear of losing their paper profits. Pretty sure that's what happened yesterday morning. Obviously we'd all rather be sitting on (larger) paper profits but today's price is not very relevant in the end if you are a LTH and believe this company is or will be worth much more than the current market cap. Of course this means that there's often little liquidity and large price swings on small trades.
I did a limit order at full ask this morning and it didn't execute. I was checking the live price and my order was "monitored" for about 10 mins with my limit being full ask. Maybe just a crap online broker I suppose, but I don't think there was much liquidity for PIs to buy.